

ONE HUNDRED NINETEENTH CONGRESS

Congress of the United States

House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6115

Majority (202) 225-3641

Minority (202) 225-2927

May 11, 2026

MEMORANDUM

To: Subcommittee on Health Members and Staff
From: Committee Majority Staff
Re: Subcommittee on Health Markup on May 13, 2026

I. INTRODUCTION

The Subcommittee on Health will hold a markup on Wednesday, May 13, 2026, at 2:00 p.m. (ET) in 2123 Rayburn House Office Building. The markup will consider the following legislation:

- H.R. 4348, To reauthorize the Kay Hagan Tick Act, and for other purposes. (Reps. Smith (NJ) and Doggett)
- H.R. 4541, EARLY Act Reauthorization of 2025 (Reps. Wasserman Schultz and Miller-Meeks)
- H.R. 3747, Accelerating Access to Dementia and Alzheimer's Provider (AADAPT) Training Act (Reps. Balderson and Barragán)
- H.R. 8209, School-Based Health Centers Reauthorization Act of 2026 (Reps. Tonko and Balderson)
- H.R. 5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025 (Reps. Smith (NJ) and Matsui)
- H.R. 8205, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 (Reps. Quigley and Calvert)
- H.R. 2715, Destruction of Hazardous Imports Act (Reps. Higgins and Carter (LA))
- H.R. 2821, FDA Modernization Act 3.0 (Reps. Carter (GA) and Barragán)
- H.R. 5347, Health Care Efficiency Through Flexibility Act (Rep. Buchanan)
- H.R. 1703, Choices for Increased Mobility Act of 2025 (Rep. Joyce (PA))

II. LEGISLATION

A. H.R. 4348, To reauthorize the Kay Hagan Tick Act, and for other purposes. (Reps. Smith (NJ) and Doggett)

H.R. 4348 would reauthorize the National Strategy and Regional Centers of Excellence in Vector-Borne Disease and the Centers for Disease Control and Prevention's (CDC) cooperative agreements with health departments in areas at high risk of vector-borne diseases through Fiscal Year 2030.

B. H.R. 4541, EARLY Act Reauthorization of 2025 (Reps. Wasserman Schultz and Miller-Meeks)

H.R. 4541 would reauthorize educational resources for breast cancer early detection through Fiscal Year 2031.

C. H.R. 3747, Accelerating Access to Dementia and Alzheimer's Provider Training Act (Reps. Balderson and Barragán)

H.R. 3747 would reauthorize the Project ECHO (Expanding Capacity for Health Outcomes) Grant Program through Fiscal Year 2031.

D. H.R. 8209, School-Based Health Centers Reauthorization Act of 2026 (Reps. Tonko and Balderson)

H.R. 8209 would reauthorize the School-Based Health Centers grant program through Fiscal Year 2031.

E. H.R. 5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025 (Reps. Smith (NJ) and Matsui)

H.R. 5160 would reauthorize the C.W. Bill Young Cell Transplantation program and the National Cord Blood Inventory program through Fiscal Year 2031.

F. H.R. 8205, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 (Reps. Quigley and Calvert)

H.R. 8205 would reauthorize and make changes to the grant award authority, expanded access program, and public-private partnership for research on therapies for ALS.

G. H.R. 2715, Destruction of Hazardous Imports Act (Reps. Higgins and Carter)

H.R. 2715 provides the Food and Drug Administration (FDA) the authority to require an importer to destroy an FDA-regulated product that was refused entry into the U.S. and presents a significant public health concern. The Secretary of HHS is responsible for determining what constitutes a significant public health concern. This bill also amends the Federal Food, Drug, and Cosmetic Act to prohibit the unauthorized movement of an article that the Secretary has designated for destruction.

H. H.R. 5347, Health Care Efficiency Through Flexibility Act (Rep. Buchanan)

H.R. 5347 would require the Secretary to make available certain collection types for quality measures that accountable care organizations (ACO) are required to report for performance years (PY) 2025 through 2029, including electronic clinical quality measures, Merit-based Incentive Payment System (MIPS) clinical quality measures, and Medicare clinical quality measures for ACOs participating in the Medicare Shared Savings Program. The bill would also require that the Secretary establish a pilot program for digital quality measure reporting for PYs 2028 through 2032.

I. H.R. 1703, Choices for Increased Mobility Act of 2025 (Rep. Joyce (PA))

H.R. 1703 would clarify coding and payment rules for manual wheelchairs under Medicare Part B to specify that coverage of manual wheelchairs does not include expenses associated with the use of titanium or carbon fiber materials to construct the base of a wheelchair. Beneficiaries covered under Medicare Part B would be permitted to pay out-of-pocket for such wheelchair upgrades. The Secretary may require suppliers to issue a notice to the individual prior to the purchase or rental of the wheelchair to inform the beneficiary of potential financial liability.

J. H.R. 2821, FDA Modernization Act 3.0 (Reps. Carter (GA) and Barragán)

H.R. 2821 would require the Secretary to publish an interim final rule to amend certain regulations to replace references of animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research.

III. STAFF CONTACTS

If you have questions regarding this hearing, please contact Annabelle Huffman of the Committee staff at (202) 225-3641.